peripher
heparin
venou
blood
sampl
obtain
seven
healthi
donor
ppd
ethic
committe
zhengzhou
univers
approv
sampl
collect
human
cell
line
transfect
cultur
imdm
supplement
fb
incub
humidifi
atmospher
contain
cell
line
provid
professor
wu
third
militari
medic
univers
china
internet
servic
bima
syfpeithi
netctl
use
epitop
predict
nativ
peptid
predict
score
rank
top
three
least
two
predict
tool
select
standard
solid
phase
fmoc
strategi
use
predict
peptid
synthesi
product
purifi
puriti
sequenc
confirm
posit
control
bind
assay
iligetiki
use
hbv
core
th
epitop
sequenc
tppayrppnapil
use
helper
epitop
vivo
assay
transgen
mice
kindli
suppli
professor
cao
second
militari
medic
univers
china
mice
bred
maintain
specif
facil
present
experi
mice
week
age
use
determin
bind
properti
candid
peptid
toward
molecul
molecul
cell
examin
accord
previous
describ
protocol
briefli
cell
incub
peptid
imdm
contain
human
sigma
st
loui
mo
usa
hr
cell
wash
twice
incub
monoclon
antibodi
wash
three
time
cell
treat
fluorescein
goat
igg
immunoglobulin
sigma
cell
harvest
analyz
facscalibur
flow
cytomet
becton
dickinson
spark
md
usa
fi
calcul
follow
formula
fi
mfi
sampl
mfi
background
mfi
background
mfi
background
repres
valu
without
peptid
cell
incub
peptid
imdm
medium
contain
hr
cell
wash
remov
free
peptid
incub
hr
cell
wash
twice
stain
analyz
flow
cytomet
defin
estim
time
requir
reduct
mfi
valu
record
time
induct
ctl
vitro
perform
accord
procedur
previous
describ
pbmc
separ
peripher
blood
ppd
healthi
donor
densiti
gradient
centrifug
cell
stimul
everi
day
peptid
imdm
medium
supplement
fb
third
day
first
stimul
subsequ
stimul
human
recombin
uml
ad
cell
employ
experi
day
three
group
transgen
mice
four
mice
group
immun
base
tail
variou
peptid
th
epitop
prepar
ifa
day
one
group
mice
receiv
ifa
contain
pb
anoth
th
peptid
use
neg
control
day
spleen
lymphocyt
cell
ml
separ
peptid
vitro
day
specif
cytotox
assay
employ
commerci
kit
human
precoat
elispot
kit
dakew
biotech
shenzhen
china
use
elispot
assay
effector
cell
stimul
cell
cell
micropl
coat
antibodi
specif
human
incub
hr
cell
remov
plate
process
number
spot
determin
automat
use
spot
analyz
dakew
biotech
method
assay
cytotox
lymphocyt
employ
base
measur
ldh
releas
target
cell
grade
e
ratio
ctl
pbmc
healthi
donor
ctl
spleen
lymphocyt
transgen
mice
briefli
cell
load
peptid
hr
use
target
cell
target
cell
variou
number
effector
cell
hr
percentag
specif
lysi
target
cell
determin
accord
follow
equat
percentag
specif
lysi
experiment
releas
effector
spontan
releas
target
spontan
releas
target
maximum
releas
target
spontan
releas
data
express
mean
sd
signific
analyz
one
way
ananlysi
varianc
p
consid
signific
statist
analys
perform
spss
first
select
three
candid
peptid
deriv
protein
optim
predict
score
predict
score
rank
top
three
least
two
predict
tool
toward
molecul
studi
tabl
peptid
involv
fragment
conserv
virul
strain
bovi
bcg
confirm
molecular
weight
peptid
tabl
evalu
bind
affin
peptid
molecul
stabil
complex
vitro
use
bind
affin
stabil
assay
label
affin
stabil
capac
nonam
peptid
fi
respect
tabl
three
candid
liasnvagv
show
highest
bind
affin
stabil
hr
toward
therefor
chose
peptid
studi
test
elispot
assay
whether
ctl
caus
releas
expand
pbmc
ppd
individu
challeng
peptid
vitro
stimul
pbmc
seven
donor
use
pb
pha
neg
posit
control
respect
induc
pbmc
two
donor
produc
fig
pha
posit
control
elicit
product
pbmc
seven
donor
pb
elicit
product
partial
data
shown
addit
perform
releas
assay
carri
ldh
releas
assay
test
cytotox
activ
ctl
induc
investig
whether
trigger
specif
function
ctl
respons
lyse
target
cell
pbmc
donor
isol
stimul
vitro
measur
cytotox
activ
respond
cell
ldh
cytotox
assay
cell
serv
target
cell
shown
fig
gener
cell
specif
lyse
cell
percentag
specif
lysi
e
ratio
prove
ctl
induc
lyse
target
cell
vitro
howev
vivo
environ
complex
import
determin
whether
peptid
natur
process
present
induc
ctl
vivo
therefor
use
transgen
mice
vivo
anim
model
shown
fig
percentag
specif
lysi
increas
e
ratio
although
mice
immun
epitop
bodi
weight
significantli
differ
control
group
mice
indic
might
low
toxic
data
shown
vivo
result
suggest
natur
process
present
induc
potent
ctl
respons
vivo
tradit
identif
cell
epitop
requir
synthesi
overlap
peptid
span
entir
length
protein
follow
experiment
assay
vitro
intracellular
cytokin
stain
peptid
assess
cell
activ
method
econom
viabl
singl
protein
pathogen
consist
sever
protein
therefor
research
develop
altern
comput
approach
predict
cell
epitop
significantli
decreas
experiment
burden
previous
associ
epitop
identif
practic
use
one
comput
algorithm
predict
ctl
epitop
may
lead
larg
number
fals
posit
fals
neg
recent
comprehens
valid
use
data
sever
differ
type
predict
softwar
prove
accur
consider
reduc
cost
epitop
discoveri
howev
differ
predict
tool
base
differ
comput
algorithm
predict
differ
choos
care
miss
immunodomin
epitop
therefor
studi
chose
three
predict
tool
base
differ
comput
algorithm
achiev
result
accur
one
approach
find
new
gener
effect
safe
vaccin
dna
vaccin
enabl
focus
immun
respons
import
highli
conserv
epitop
approach
provid
opportun
use
specif
epitop
shift
immun
system
toward
immun
respons
elimin
unwant
respons
addit
ctl
immun
advantag
elicit
immun
respons
protect
epitop
avoid
epitop
drift
tuberculosi
infect
studi
tuberculosi
human
shown
induct
broad
mediat
immun
tuberculosi
type
cytokin
includ
could
essenti
tb
vaccin
design
vaccin
base
ctl
epitop
repres
logic
approach
gener
effect
cellular
immun
prophylact
therapeut
set
multipl
epitop
incorpor
vaccin
design
goal
induc
broadli
reactiv
respons
multipl
ctl
clone
direct
differ
epitop
epitop
dna
vaccin
report
induc
broad
ctl
respons
hiv
hbv
sever
acut
respiratori
syndrom
coronaviru
other
wherea
vaccin
limit
respect
hla
polymorph
popul
coverag
use
epitop
provid
mean
address
problem
conclus
identifi
novel
cell
epitop
deriv
result
show
liasnvagv
could
serv
candid
peptid
vaccin
tuberculosi
conflict
interest
